important in light of the COVID-19 pandemic, which has seen reduced screening numbers, which are projected to result in increased late-stage diagnoses. More on NCCN’s message that “Cancer Won’t Wait and Neither Should You” can be found at NCCN
Search Results
Dingcheng Shen, Xiaolin Wang, Heng Wang, Gaopo Xu, Yumo Xie, Zhuokai Zhuang, Ziying Huang, Juan Li, Jinxin Lin, Puning Wang, Meijin Huang, Yanxin Luo, and Huichuan Yu
-specific mortality. It is well-known that elevated circulating CEA levels can also be found in some benign statuses and inflammation-derived diseases, such as COVID-19, 39 , 40 and the specificity of CEA for diagnosing primary gastrointestinal tumors is limited
comparable age, and 13% preferred someone of their own gender. One patient was unable to fill out baseline surveys due to worsening of their medical condition. Due to the COVID-19 pandemic, the trial was closed for the eight months but is now open to accrual
Alex J. Ball, Imran Aziz, Sophie Parker, Ravishankar B. Sargur, Jonathan Aldis, and Matthew Kurien
generated controversy and been used to mitigate pressure on endoscopic and radiologic resources, which have been impacted by the COVID-19 pandemic. 20 Future work needs to evaluate this evolving use of FIT to ensure appropriate triaging and prioritization
Lindsey Bandini, Alyssa Schatz, Victoria Hood, Nikia Clark, Michael J. Hall, and Robert W. Carlson
COVID-19 pandemic. Therefore, the timing is opportune to highlight recent successes across the field, while acknowledging where gaps still exist. Dr. Lisa Richardson, Director of the Division of Cancer Prevention and Control within the CDC, delivered a
.” The speakers offered many insights on leveraging technology to serve more patients. They acknowledged the massive expansion in telehealth was one positive thing to come from the COVID-19 pandemic. However, panel members pointed out that there is still
Presented by: Mazyar Shadman and Deborah M. Stephens
to flow cytometry for MRD testing,” he added. All 3 doctors agreed that the COVID-19 pandemic is shifting their thinking favoring small molecule inhibitors. “In this current situation we want to preserve immune function and try not to choose a therapy
Presented by: Chad A. LaGrange, M. Dror Michaelson, and Colleen H. Tetzlaff
of disease. The patient has no symptoms of disease, normal lab evaluations, and was working full-time until the COVID-19 pandemic. Case 2 was of a 51-year-old man with gross hematuria seen in September 2018. Initial management at that time was
Jennifer M. Snaman, Deborah Feifer, Gabrielle Helton, Yuchiao Chang, Areej El-Jawahri, Angelo E. Volandes, and Joanne Wolfe
allow for virtual enrollment and study completion due to the COVID-19 pandemic. After the initial mailed letter, eligible participants were called to provide further study details and assess interest. Members of the dyads completed study components on
Xudong Ni, Michael Luu, Weiwei Ma, Tingwei Zhang, Yu Wei, Stephen J. Freedland, Dingwei Ye, Timothy J. Daskivich, and Yao Zhu
patients during the COVID-19 pandemic . JAMA Oncol 2021 ; 7 : 1467 – 1473 . 34292311 8. Loeb S , Borno HT , Gomez S , Representation in online prostate cancer content lacks racial and ethnic diversity: implications for Black and